Suppr超能文献

降低体内彗星试验中假阳性的风险并提高结果可靠性。

Reducing risk of false positives in the in vivo comet assay and improving result reliability.

机构信息

Helix3 Inc., USA.

Helix3 Inc., USA.

出版信息

Mutat Res Genet Toxicol Environ Mutagen. 2024 Apr;895:503750. doi: 10.1016/j.mrgentox.2024.503750. Epub 2024 Mar 15.

Abstract

The risk of generating false positive in vivo comet assay results can be increased when procedural bias and/or technical variability is poorly controlled. This has been an ongoing concern since comet was first introduced into regulatory safety testing. But the proprietary nature of regulated studies and the 3Rs have limited the ability to conduct and publish the comparative in vivo studies necessary to determine the effect these factors can have on comet assay results when substances other than well characterized positive control compounds are evaluated in multiple tissues. That changed when Helix3 was asked to repeat for regulatory submission three independent in vivo comet studies with positive results generated by three other laboratories evaluating the effects of three different test substances on the liver, duodenum, and stomach. We repeated each study using the same test substance and experimental design as the original labs but with our standard quality control methods implemented to reduce procedural bias and variability. In every case, we generated negative results that regulatory authorities accepted over the initial positive results due to evidence of high technical variability and procedural bias in the original labs and studies. Meanwhile, the International Workshop on Genotoxicity (IWGT) compared >14 years of Helix3 comet historical control data (HCD) to HCD from 6 other experienced comet laboratories and concluded that our data exhibited the highest overall background % tail DNA levels with the lowest inter-study variability resulting in the highest quality HCD of all the labs evaluated. These case studies and the IWGT report suggest that our enhanced quality control methods and higher (>2 % mean of slide median tail DNA) background levels can effectively mitigate the nuisance factors that can generate false positive in vivo comet assay results. To facilitate a better understanding of the technical parameters that can significantly influence the comet results, we describe our enhanced procedures with justifications and examples.

摘要

当程序偏差和/或技术变异性控制不佳时,体内彗星试验结果产生假阳性的风险可能会增加。自从彗星首次引入监管安全测试以来,这一直是一个持续存在的问题。但是,受监管研究的专有性质和 3R 原则限制了进行和发表必要的体内比较研究的能力,这些研究旨在确定当除了经过充分表征的阳性对照化合物以外的物质在多个组织中进行评估时,这些因素对彗星试验结果的影响。当 Helix3 被要求重复进行监管提交的三项独立的体内彗星研究时,这种情况发生了变化,这三项研究的阳性结果是由其他三个实验室产生的,评估了三种不同的测试物质对肝脏、十二指肠和胃的影响。我们使用与原始实验室相同的测试物质和实验设计重复了每项研究,但采用了我们的标准质量控制方法来减少程序偏差和变异性。在每种情况下,由于原始实验室和研究中存在高技术变异性和程序偏差的证据,我们生成了负面结果,监管机构接受了最初的阳性结果。与此同时,遗传毒性国际研讨会(IWGT)将 Helix3 彗星历史对照数据(HCD)与来自其他 6 个经验丰富的彗星实验室的 HCD 进行了 >14 年的比较,并得出结论,我们的数据显示出最高的总体背景 %尾 DNA 水平,以及最低的组间研究变异性,导致所有评估的实验室中具有最高质量的 HCD。这些案例研究和 IWGT 报告表明,我们增强的质量控制方法和更高的(>2%的平均载玻片中位数尾 DNA)背景水平可以有效减轻可能导致体内彗星试验结果产生假阳性的麻烦因素。为了更好地理解可能显著影响彗星结果的技术参数,我们描述了我们的增强程序,并提供了理由和示例。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验